Modern pathologic diagnostics of breast cancer;Az emlorák korszeru patológiai diagnosztikája

Orvosi Hetilap

Volumn 153, Issue 1, 2012, Pages 22-30

  Szőke, János ^a,b   Udvarhelyi, Nóra ^a  

^a Sebészi És Molekuláris Daganatpatológiai Centrum   (Hungary)

^b NONE   (Hungary)

Author keywords

breast cancer; molecular classifi cation; pathology; predictive markers; prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; GENE EXPRESSION PROFILING; LYMPH NODE; MEDICAL LITERATURE; MOLECULAR DIAGNOSIS; PATHOLOGY; PATIENT CARE; PROGNOSIS; TUMOR VOLUME;

EID: 84855262931     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2012.29251     Document Type: Article

References (50)

1. Blamey, R. W.: The design and clinical use of the Nottingham Prognostic Index in breast cancer. Breast, 1996, 5, 156-157.
2. Eifel, P., Axelson, J. A., Costa, J., et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J. Natl. Cancer Inst., 2001, 93, 979-989.
3. Goldhirsch, A., Ingle, J. N., Gelber, R. D., et al.: Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol., 2009, 20, 1319-1329.
4. Adjuvant! Online. http://www.adjuvantonline.com/index.jsp (megtekintve: 2011. szeptember 17.).
5. Lester, S. C., Bose, S., Chen, Y. Y., et al.: Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch. Pathol. Lab. Med., 2009, 133, 1515-1538.
6. Association of Directors of Anatomic and Surgical Pathology. Checklists and Guidelines. http://www.adasp.org/Checklists/checklists.htm (megtekintve: 2011. szeptember 17.).
7. Tóth, J., Cserni, G., Kálmán, E., et al.: Az emlrák patológiai feldolgozása és leletezése. Magy. Onkol., 2000, 44, 14-16.
8. Cserni, G., Francz, M., Járay, B., et al.: Pathologic diagnosis and histopathology record of breast cancer. [Az emlrák patológiai diagnosztikája, feldolgozása és kórszövettani leletezése.] Magy. Onkol., 2010, 54, 217-226. [Hungarian]
9. Fisher, E. R., Anderson, S., Redmond, C., et al.: Pathologic fi nd-ings from the National Surgical Adjuvant Breast Project Protocol B-06. 10 year pathologic and clinical discriminants. Cancer, 1993, 71, 2507-2514. (Pubitemid 23100484)
10. Carter, C. L., Allen, C., Henson, D. E.: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer, 1989, 63, 181-187. (Pubitemid 19032001)
11. Lee, A. H. S., Ellis, I. O.: The Nottingham Prognostic Index for invasive carcinoma of the breast. Pathol. Oncol. Res., 2008, 14, 113-115.
12. Elston, C. W., Ellis, I. O.: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: expe-rience from a large study with long-term follow-up. Histopathol-ogy, 1991, 19, 403-410.
13. Blamey, R. W., Ellis, I. O., Pinder, S. E., et al.: Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur. J. Cancer, 2007, 43, 1548-1555. (Pubitemid 46901016)
14. Frkovic-Grazio, S., Bracko, M.: Long term prognostic value of Nottingham prognostic histological grade and its components in early (pT1N0M0) breast carcinoma. J. Clin. Pathol., 2002, 55, 88-92. (Pubitemid 34123906)
15. Volpi, A., Bacci, F., Paradiso, A., et al.: Prognostic relevance of histological grade and its components in node negative cancer patients. Mod. Pathol., 2004, 17, 1038-1044. (Pubitemid 39128229)
16. Boiesen, P., Bendahl, P. O., Anagnostaki, L., et al.: Histologic grading in breast cancer: reproducibility between seven pathologic departments. Acta. Oncol., 2000, 39, 41-45. (Pubitemid 30216614)
17. Rakha, E. A., Reis-Filho, J. S., Baehner, F., et al.: Breast cancer prognostic classifi cation in the molecular era: the role of histo-logical grade. Breast Cancer Res., 2010, 12, 207-219.
18. Bland, K. I., Menck, H. R., Scott-Conner, C. E., et al.: The National Cancer Center Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer, 1998, 83, 1262-1273. (Pubitemid 28419082)
19. Fitzgibbons, P. L., Page, D. L., Weaver D., et al.: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med., 2000, 124, 966-978.
20. Sahoo, S., Lester, S. C.: Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch. Pathol. Lab. Med., 2009, 133, 633-642.
21. Allred, D. C.: Issues and updates: evaluating estrogen receptor-alfa, progesterone receptor, and HER2 in breast cancer. Mod. Pathol., 2010, 23, S52-S59.
22. Colleoni, M., Viale, G., Zahrieh, D.: Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res., 2004, 10, 6622-6628. (Pubitemid 39346559)
23. Cserni, G., Francz, M., Kálmán, E., et al.: Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they? Pathol. Oncol. Res., 2011, 17, 663-668.
24. Bardou, V. J., Arpino, G., Elledge, R. M., et al.: Progesterone receptor status signifi cantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol., 2003, 21, 1973-1979. (Pubitemid 46606386)
25. Hammond, E. M. H., Allred, D. C., Dowsett, M., et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen/progesterone receptors in breast cancer. Arch. Pathol. Lab. Med., 2010, 134, 907-922.
26. Wolff, A. C., Hammond, E. H., Schwartz, J. N., et al.: American Society of Clinical Oncology/College of American Patholo-gists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol., 2007, 25, 118-145. (Pubitemid 350003059)
27. Schnitt, J.: Classifi cation and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod. Pathol., 2010, 23, S60-S64.
28. Leong, A. S., Zhunag, Z.: The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology, 2011, 78, 99-114.
29. Gruver, A. M., Portier, B. P., Tubbs, R. R.: Molecular pathology of breast cancer. The journey from traditional practice toward embracing the complexity of a molecular classifi cation. Arch. Pathol. Lab. Med., 2011, 135, 544-557.
30. Correa Geyer, F., Reis-Filho, J. S.: Microarray-based gene expression profi ling as clinical tool for breast cancer management: are we there yet? Int. J. Surg. Pathol., 2009, 17, 285-302.
31. Sotiriou, C., Pusztai, L.: Gene-expression signatures in breast cancer. N. Engl. J. Med., 2009, 360, 790-800.
32. Sorlie, T., Perou, C. M., Tibshirani, R., et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 10869-10874. (Pubitemid 32878711)
33. Sorlie, T., Tibshirani, R., Parker, J., et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 8418-8423. (Pubitemid 36842560)
34. Rakha, E., Reis-Filho, J. S.: Basal-like breast carcinoma: from expression profi ling to routine practice. Arch. Pathol. Lab. Med., 2009, 133, 860-868.
35. Carey, L. A., Dees, E. C., Sawyer, L., et al.: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res., 2007, 13, 2329-2334. (Pubitemid 46698581)
36. Liedtke, C., Mazouni, C., Hess, K. R., et al.: Response to neoad-juvant therapy and longterm survival in patients with triple-negative breast cancer. J. Clin. Oncol., 2008, 26, 1275-1281.
37. Turner, N. C., Reis-Filho, J. S., Russell, A. M., et al.: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene, 2007, 26, 2126-2132. (Pubitemid 46514749)
38. Cheang, M. C. U., Chia, S. K., Voduc, D., et al.: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J. Natl. Cancer Inst., 2009, 101, 736-750.
39. Cheang, M. C., Vodue, D., Bajdik, C.: Basallike breast cancer de-fi ned by fi ve biomarkers has superior prognostic value than triple negative phenotype. Clin. Cancer Res., 2008, 14, 1368-1376. (Pubitemid 351413917)
40. Weigelt, B., Horlings, H. M., Kreike, B., et al.: Refi nement of breast cancer classifi cation by molecular characterization of his-tological special types. J. Pathol., 2008, 216, 141-150.
41. Ivshina, A. V., George, J., Senko, O., et al.: Genetic reclassifi cation of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res., 2006, 66, 10292-10301. (Pubitemid 44799747)
42. Sotiriou, C., Wirapati P., Loi, S., et al.: Gene expression profi ling in breast cancer: understanding the molecular basis of his-tologic grade to improve prognosis. J. Natl. Cancer Inst., 2006, 98, 262-272. (Pubitemid 43264710)
43. Sotiriou, C., Piccart, M. J.: Taking gene-expression profi ling to the clinic: when will molecular signatures become relevant to patient care? Nat. Rev. Cancer, 2007, 7, 545-553. (Pubitemid 46985399)
44. Wirapati, P., Sotiriou, C., Kunkel, S., et al.: Meta-analysis of gene expression profi les in breast cancer: toward a unifi ed understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res., 2008, 10, R65.
45. Paik, S., Shak, S., Tang, G., et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med., 2004, 351, 2817-2826. (Pubitemid 40051905)
46. Sparano, J. A., Paik, S.: Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol., 2008, 26, 721-728. (Pubitemid 351264384)
47. Van de Vijver, M. J., He, Y. D., van Veer, L. J., et al.: A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 2002, 347, 1999-2009. (Pubitemid 35461656)
48. Buyse, M., Loi, S., van't Veer, L., et al.: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst., 2006, 98, 1183-1192. (Pubitemid 44390989)
49. Cardoso, F., van't Veer, L., Rutgers, E., et al.: Clinical application of the 70-gene profi le: the MINDACT trial. J. Clin. Oncol., 2008, 26, 729-735. (Pubitemid 351264385)
50. Flanagan, M. B., Dabbs, D. J., Brufsky, A. M., et al.: Histopatho-logic variables predict Oncotype DX Recurrence Score. Mod. Pathol. 2008, 21, 1255-1261.